Vanessa Villar, MD
Family Medicine · Elkton, MDNPI 1639136104
Payments from drug & device makers
Across 289 payments — averaging $28.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Lilly USA, LLC$931
- Novo Nordisk$630
- GSK$571
- Amgen$482
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,272100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $1,094 |
| AstraZeneca | 20 | $1,011 |
| Lilly USA, LLC | 29 | $931 |
| Novo Nordisk | 33 | $630 |
| GSK | 6 | $571 |
| Amgen | 20 | $482 |
| Abbott | 7 | $468 |
| Boehringer Ingelheim | 3 | $363 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $321 |
| Pfizer | 15 | $287 |
| Phathom Pharmaceuticals, Inc. | 10 | $254 |
| Astellas Pharma US Inc | 14 | $232 |
| Esperion Therapeutics, Inc. | 5 | $191 |
| Merck | 12 | $185 |
| Eisai Inc. | 6 | $176 |
| Johnson & Johnson | 3 | $154 |
| Sanofi-aventis U.S. LLC | 1 | $120 |
| Avanir Pharmaceuticals, Inc. | 1 | $105 |
| Exact Sciences | 5 | $104 |
| Biohaven Pharmaceuticals, Inc. | 5 | $94 |
| Amarin Pharma, Inc. | 1 | $90 |
| Sanofi Pasteur Inc. | 3 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Tactile Systems Technology Inc | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Bristol Myers Squibb | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Dermira, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$475
- UBRELVY$352
- FreeStyle Libre 2$279
- AIRSUPRA$259
- TRELEGY ELLIPTA$243
- QULIPTA$234
- FARXIGA$234
- FREESTYLE LIBRE 3$143
- XARELTO$125
- Otezla$125
- VOQUEZNA$125
- MOUNJARO$125
- NEXLIZET$120
- NEXLETOL$120
- SOLIQUA 100/33$120
- ZEPBOUND$115
- VIBERZI$115
- Ozempic$111
- AREXVY$108
- NUEDEXTA$105
How this compares
$8,272 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 54 | $56,097 |
| EliquisApixaban | 20 | $29,917 |
| OzempicSemaglutide | 24 | $25,769 |
| FarxigaDapagliflozin Propanediol | 22 | $23,770 |
| MyrbetriqMirabegron | 19 | $21,298 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $12,368 |
| Tegretol XrCarbamazepine | 20 | $5,459 |
| Atorvastatin Calcium | 381 | $4,766 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,074 |
| Aripiprazole | 15 | $4,013 |
| Rosuvastatin Calcium | 161 | $2,757 |
| Levothyroxine Sodium | 250 | $2,132 |
| Ezetimibe | 46 | $2,094 |
| Lisinopril | 281 | $2,087 |
| SynthroidLevothyroxine Sodium | 28 | $2,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $185 | $56,09754 claims |
| PfizerEliquis | $287 | $29,91720 claims |
| Novo NordiskOzempic | $630 | $25,76924 claims |
| AstraZenecaFarxiga | $1,011 | $23,77022 claims |
| Astellas Pharma US IncMyrbetriq | $232 | $21,29819 claims |
| GSKAnoro Ellipta, Incruse Ellipta | $571 | $16,44224 claims |
| AbbVieSynthroid | $1,094 | $2,04628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Elkton
- Ozden CoksayganElkton$39K
- Edwin Gar-ElElkton$26K
- Lisa WardElkton$23K
- John MulveyElkton$12K
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.